PMID:
Oxid Med Cell Longev. 2019 ;2019:7850863. Epub 2019 Mar 31. PMID: 31049139
Abstract Title:
Improves Chronic Kidney Disease by Affecting TLR4/NF-B Redox Signaling Pathway.
Abstract:
may show good promise in protecting against chronic kidney disease (CKD) but the molecular mechanism remains unclear. CKD risk is associated with the Toll-like receptor 4/nuclear factor-kappa B (TLR4/NF-B) signaling pathway. Cordycepin is the main component ofand may affect the TLR4/NF-B pathway. Cordycepin was prepared by preparative HPLC. CKD patients were assigned into(COG, 100 mg daily) and placebo (CG) groups. Cordycepin activity was measured using human embryo kidney cells (HEK293T). Biochemical indices, the levels of TLR4, NF-B, cyclooxygenase-2 (COX2), tumor necrosis factor-alpha (TNF-), and interleukin-1 beta (IL-1), were measured by real-time qRT-PCR, or ELISA kits and or Western blot. After 3-month treatment, cordycepin reduced the levels of urinal protein, blood urea nitrogen (BUN), and creatinine by 36.7%±8.6%, 12.5%±3.2%, and 18.3%±6.6%, respectively (
Health Time 